CENTAGEN Trademark

Trademark Overview

On Friday, June 17, 2022, a trademark application was filed for CENTAGEN with the United States Patent and Trademark Office. The USPTO has given the CENTAGEN trademark a serial number of 97980668. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Friday, September 19, 2025. This trademark is owned by Centagen, Inc.. The CENTAGEN trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Biochemical research; Biochemical research and development; Biotechnology research; Pharmaceutical research and development; Research and development in the field of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of cardiovascular, immune system and inflammatory related diseases and disorders; Scientific research; Stem cell research services; Research and development of pharmaceuticals for the treatment of age-related diseases
centagen

General Information

Serial Number97980668
Word MarkCENTAGEN
Filing DateFriday, June 17, 2022
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateFriday, September 19, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 19, 2023

Trademark Statements

Goods and ServicesBiochemical research; Biochemical research and development; Biotechnology research; Pharmaceutical research and development; Research and development in the field of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of cardiovascular, immune system and inflammatory related diseases and disorders; Scientific research; Stem cell research services; Research and development of pharmaceuticals for the treatment of age-related diseases

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, July 6, 2022
Primary Code042
First Use Anywhere DateTuesday, March 3, 2009
First Use In Commerce DateMonday, June 28, 2010

Trademark Owner History

Party NameCentagen, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBoulder, CO 80305
Party NameCentagen, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoulder, CO 80305

Trademark Events

Event DateEvent Description
Wednesday, July 6, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 29, 2023ASSIGNED TO EXAMINER
Thursday, June 8, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, November 12, 2023ASSIGNED TO LIE
Monday, November 13, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 21, 2022NEW APPLICATION ENTERED
Wednesday, March 29, 2023NON-FINAL ACTION WRITTEN
Wednesday, March 29, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 29, 2023NON-FINAL ACTION E-MAILED
Monday, November 13, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, November 13, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 29, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 19, 2023PUBLISHED FOR OPPOSITION
Tuesday, December 19, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, August 12, 2024SOU TEAS EXTENSION RECEIVED
Monday, August 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 12, 2024SOU EXTENSION 1 FILED
Thursday, February 13, 2025DIVISIONAL REQUEST RECEIVED
Thursday, February 13, 2025USE AMENDMENT FILED
Thursday, February 13, 2025TEAS REQUEST TO DIVIDE RECEIVED
Wednesday, April 30, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, September 16, 2025STATEMENT OF USE PROCESSING COMPLETE
Tuesday, February 13, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, September 3, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, August 12, 2024SOU EXTENSION 1 GRANTED
Thursday, February 13, 2025TEAS STATEMENT OF USE RECEIVED
Tuesday, September 16, 2025DIVISIONAL PROCESSING COMPLETE
Friday, September 19, 2025ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, September 19, 2025NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

Related Keywords

centagen research development biochemical pharmaceuticals related pharmaceutical diseases treatment disorders stem